title: Serum periplakin as a potential biomarker for urothelial carcinoma of the urinary bladder.
abstract: The objectives of this study were to examine serum periplakin expression in patients with urothelial carcinoma of the urinary bladder and in normal controls, and to examine relationships with clinicopathological findings. Detection of serum periplakin was performed in 50 patients and 30 normal controls with anti-periplakin antibodies using the automatic dot blot system, and a micro-dot blot array with a 256 solid-pin system. Levels in patients with urothelial carcinoma of the urinary bladder were significantly lower than those in normal controls (0.31 and 5.68, respectively; p<0.0001). The area under the receiver-operator curve level for urothelial carcinoma of the urinary bladder was 0.845. The sensitivity and specificity, using a cut-off point of 4.045, were 83.7% and 73.3%, respectively. In addition, serum periplakin levels were significantly higher in patients with muscle-invasive cancer than in those with nonmuscle-invasive cancer (P=0.03). In multivariate Cox proportional hazards regression analysis, none of the clinicopathological factors was associated with an increased risk for progression and cancer-specific survival. Examination of the serum periplakin level may play a role as a non- invasive diagnostic modality to aid urine cytology and cystoscopy.
authors.affiliation: Departments of Urology, School of Medicine, Kitasato University, Japan E-mail : kazumasa@cd5.so-net.ne.jp.
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Matsumoto
authors.forename: Masaomi
authors.initials: M
authors.lastname: Ikeda
authors.forename: Toshihide
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Ryo
authors.initials: R
authors.lastname: Nagashio
authors.forename: Takanori
authors.initials: T
authors.lastname: Nishimori
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tomonaga
authors.forename: Fumio
authors.initials: F
authors.lastname: Nomura
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Sato
authors.forename: Hidero
authors.initials: H
authors.lastname: Kitasato
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Iwamura
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D003558:Cystoscopy; D003581:Cytodiagnosis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D019042:Muscle Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D051179:Plakins / Q000097:blood*; D011379:Prognosis; D012372:ROC Curve; D012189:Retrospective Studies; D015996:Survival Rate; D001743:Urinary Bladder / Q000378:metabolism*; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000401:mortality
chemical_list: D014408:Biomarkers, Tumor; C491674:PPL protein, human; D051179:Plakins